Compare
Nautilus Biotechnology, Inc. vs 908 Devices Inc. vs Seer, Inc. vs EyePoint, Inc.
| Latest fiscal year | Nautilus Biotechnology, Inc. NAUT | 908 Devices Inc. MASS | Seer, Inc. SEER | EyePoint, Inc. EYPT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $56.20M | $16.58M | $31.37M |
| Revenue growth (YoY) | n/a | +17.7% | +17.0% | -27.5% |
| Gross margin | n/a | 50.6% | 51.1% | n/a |
| Operating margin | n/a | -70.1% | -470.5% | -776.0% |
| Net margin | n/a | 34.7% | -444.0% | -739.4% |
| Net income | -$59.00M | $19.49M | -$73.60M | -$231.96M |
| EPS (Diluted) | -$0.47 | $0.54 | n/a | -$3.17 |
| Operating cash flow | -$50.70M | -$23.69M | -$44.45M | -$240.11M |
| Free cash flow | -$51.97M | -$24.64M | -$46.24M | -$243.39M |
| Cash & equivalents | $12.39M | $70.52M | $47.28M | $101.82M |
| Total assets | $191.11M | $190.07M | $296.08M | $364.00M |
| Total liabilities | $34.14M | $46.37M | $36.78M | $57.88M |
| Shareholders' equity | $156.97M | $143.70M | $259.31M | $306.11M |
| Return on year-end equity | -37.6% | 13.6% | -28.4% | -75.8% |
| Shares outstanding | 126.47M | 36.32M | n/a | 82.83M |
Revenue, most recent five fiscal years
| Fiscal year | Nautilus Biotechnology, Inc. | 908 Devices Inc. | Seer, Inc. | EyePoint, Inc. |
|---|---|---|---|---|
| Latest | n/a | $56.20M Ended 2025-12-31 | $16.58M Ended 2025-12-31 | $31.37M Ended 2025-12-31 |
| 1 year earlier | n/a | $47.75M Ended 2024-12-31 | $14.17M Ended 2024-12-31 | $43.27M Ended 2024-12-31 |
| 2 years earlier | n/a | $50.23M Ended 2023-12-31 | $16.66M Ended 2023-12-31 | $46.02M Ended 2023-12-31 |
| 3 years earlier | n/a | $46.85M Ended 2022-12-31 | $15.49M Ended 2022-12-31 | $41.40M Ended 2022-12-31 |
| 4 years earlier | n/a | $42.21M Ended 2021-12-31 | $6.62M Ended 2021-12-31 | $36.94M Ended 2021-12-31 |